🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Finland's Orion eyes US sales boost with blockbuster prostate cancer drug

Published 09/26/2024, 08:46 AM
Updated 09/26/2024, 08:51 AM
© Reuters.
MRK
-
BAYRY
-

By Anne Kauranen

HELSINKI (Reuters) - Finnish drugmaker Orion wants to boost sales in the United States on the back of the success of its prostate cancer drug Nubeqa, which it is developing jointly with German partner Bayer (OTC:BAYRY), Orion's chief executive Liisa Hurme told Reuters.

The two companies announced on Thursday that sales of Nubeqa have been worth more than a billion euros this year, making it Orion's first "blockbuster" product, and that Bayer is seeking approval from U.S. authorities to expand its use to a new patient group.

Nubeqa, also known as darolutamide, is Bayer's third best selling drug globally with sales growing most rapidly in the U.S., Hurme said.

That encouraged Orion to establish a research centre in the U.S. last year, with an eye on growth opportunities in a country that accounts for roughly half of the world's drug market, Hurme said.

"We are in the U.S. in order to develop our own innovations in that market ourselves," she said, referring to Orion's ODM-111 molecule for pain treatment and Orion's cooperation with U.S. based drugmaker Merck & Co in the development of opevesostat, used against metastatic castration-resistant prostate cancer, among other products.

"Pain is highly undertreated and especially in the U.S., the use of opiates is a major problem," she added, referring to the expansion of drug misuse.

Bayer said it was submitting an application to the U.S. Food and Drug administration for a third indication for darolutamide to be used in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, following a successful phase III trial.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.